Abstract Details

Title Hypersomnolence is a Significant Predictor of New Medical Conditions Among Elderly People in a Longitudinal Study of the General Population

Topic Sleep

Presentation(s) S3 - Sleep Medicine: Highlights 2020 (1:36 PM-1:48 PM)

Poster/Presentation
Number 004

Background Hypersomnolence was frequently found to be a risk factor for several psychiatric disorders. It has also been associated with cognitive decline and Alzheimer’s disease. Its role in the development of other medical conditions has been seldomly investigated in the general population.

Objective To investigate if hypersomnolence is a risk factor for the appearance of certain medical conditions in older adults.

Design/Methods This longitudinal study was carried out in eight states in the U.S. A total of 12,218 subjects were interviewed by phone during the first wave (W1) and 10,930 at the second wave (W2) three years apart. The analyses included only the subjects who participated in the 2 waves (N=10,930). Hypersomnolence symptoms were assessed according to DSM-5 criteria. At W2, 3,701 participants were at least 65 year-old and 59.3% were women.

Results

A total of 22.7% of the elderly participants reported hypersomnolence at W1 and 23.7% at W2. The hypersomnolence was chronic for 40.9% of them. After adjusting for gender and obstructive sleep apnea, Hypersomnolence at W1 was a risk factor for the development of diabetes at W2 (RR: 2.3 [1.5-3.4]), cancer at W2 (RR: 2.0 [1.1-3.8]) and hypertension at W2 (RR: 2.3 [1.5-3.4]). Hypersomnolence at W1 (RR: 1.8 [1.3-2.5]) and chronic hypersomnolence (i.e., present at W1 & W2) (RR: 2.5 [1.8-3.4]) were risk factors for the development of a heart disease at W2. Hypersomnolence at W2 was associated with diseases of the musculoskeletal system and connective tissue at W2 (OR: 1.5 [1.1-2.0]).

Conclusions The results suggest that hypersomnolence in the elderly individuals can be an early sign of a developing medical condition. Physicians need to pay closer attention to their patients reporting hypersomnolence.

Authors/Disclosures
Maurice M. Ohayon, MD, PhD, DSc (Stanford) PRESENTER	The institution of Dr. Ohayon has received research support from Jazz pharmaceuticals. The institution of Dr. Ohayon has received research support from Takeda Pharmaceuticals.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��